Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Zacks Investment Research

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, April 4th. The firm currently has a $1.50 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 2.74% from the company’s current price.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 29th.

Shares of NASDAQ CAPR opened at $1.46 on Wednesday. Capricor Therapeutics has a 1 year low of $0.63 and a 1 year high of $4.25.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.63 million. analysts predict that Capricor Therapeutics will post -0.42 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of CAPR. Wells Fargo & Company MN acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $107,000. Jane Street Group LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $190,000. Belpointe Asset Management LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $249,000. Finally, Brown Advisory Inc. acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $1,796,000. Institutional investors own 8.78% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Zacks Investment Research” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://weekherald.com/2018/04/20/capricor-therapeutics-capr-upgraded-to-buy-at-zacks-investment-research.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply